"1. An Evidence Based Approach to Immunosuppression in Jan, 2007",
"2. Disclosures",
"3. Transplantation: The Pharmacy Supermarket Shopping Bag",
"4. New Trends in Immunosuppression",
"5. TOLERANCE IS THE GOAL",
"6. COMBINATION IMMUNOSUPPRESSION",
"7. FACTORS DETERMINING CHOICE OF IMMUNOSUPPRESSION",
"8. INDIVIDUALIZATION OF IMMUNOSUPPRESSION",
"9. Immunosuppression Action Halloran NEJM, 2005",
"10. Benefits of OKT3 In High Risk Donors",
"11. Benefits of OKT3 In Highly Sensitized Patients", 
"12. Rabbit Anti Thymocyte Serum vs OKT3", 
"13. Current Use of Antilymphocyte Products", 
"14. Rabbit Antithymocyte Globulin versus Basiliximab for Induction in Renal Transplantation", 
"15. Study Entry Criteria: CIT>24 hours", 
"16. Study Entry Criteria: CIT 16 to 24 hours", 
"17. ", 
"18. Study Treatments: Induction Therapy", 
"19. Efficacy Endpoints at 12 Months", 
"20. Should CD25 Antibodies be Used for Low Risk Transplants?", 
"21. CO-STIMULATION BLOCKADE WITH LEA29Y IN A CALCINEURIN INHIBITOR-FREE MAINTENANCE REGIMEN:6 MONTH EFFICACY AND SAFETY", 
"22. LEA29Y-Renal Transplant Trial", 
"23. LEA29Y Phase II Dose-Finding Study Design", 
"24. Incidence of Acute Rejection at Six Months", 
"25. Graft Loss and Death Rates*", 
"26. Mean(sd)Measured GFR(mL, min)", 
"27. CURRENT USE OF ANTI-LYMPHOCYTE PRODUCTS", 
"28. Why Minimize Steroids?", 
"29. Later Steroid Withdrawal At Several Months or Later", 
"30. Patient Drug Preference Prasad et al Clin Transplant 17;135,2003", 
"31. European Steroid-Withdrawal Trial With MMF and CsA", 
"32. US Steroid-Withdrawal Trial With MMF and CsA", 
"33. Meta-analysis of Steroid Withdrawal Trials Pascual et al, Transplantation, 2004", 
"34. ", 
"35. ",
"36. SLOW WITHDRAWAL OF STEROIDS Cardella et al Personal Communication", 
"37. STEROID DISCONTINUATION IN CANADIAN TACROLIMUS VS NEORAL LIVER TRIAL Greig et al Liver Transplantation 9;587,2003", 
"38. Early Steroid Withdrawal", 
"39. CARMEN Steroid Avoidance Study Rostaing et al Transplantation, 2005", 
"40. Biopsy proven acute rejection 6-month", 
"41. Renal function and rejection incidence in de novo renal transplant patients randomized to steroid avoidance, steroid withdrawal or standard steroids", 
"42. FREEDOM study design", 
"43. ", 
"44. ", 
"45. ", 
"46. ",
"47. ",
"48. ",
"49. ",
"50. ",
"51. Design: Prospective, Double-Blind, Stratified", 
"52. Efficacy and Safety Endpoints", 
"53. Inclusion Criteria", 
"54. Immunosuppression", 
"55. Conclusions", 
"56. Which Calcineurin Inhibitor is Better, Neoral(Cyclosporine) or Prograf(Tacrolimus)", 
"57. Which Calcineurin Inhibitor is Better, Neoral or Prograf?", 
"58. Efficacy of Sandimmune(CSA) vs Prograf", 
"59. RCT of Tacrolimus vs CSA Microemulsion(C0) Kramer et al NDT 2005", 
"60. Renal Function:Neoral vs Tacrolimus Kaplan et al, 2003", 
"61. Renal Function Kramer et al DDT, 2005", 
"62. Renal Function CSA Microemulsion (C2) vs Tacrolimus Kim et al Transplantation, 2006", 
"63. ", 
"64. New Onset Diabetes CSA ME vs TAC Kim et al Transplantation, 2006", 
"65. CSA ME C2 vs Tacrolimus C0", 
"66. Acute Rejection in Renal Transplantation CSA ME vs Tacrolimus Kramer et al NDT, 2005", 
"67. Li2st:Incidence of rejection, graft loss, death by 6 months in liver RCT Levy et al Transplantation, 2004",
"68. MYCOPHENOLIC ACID DERIVATIVES",
"69. RCT of MMF vs Azathioprine with CSA ME",
"70. MMF and Chronic Allograft Failure Ojo et al Transplantation 69;2405,2000",
"71. ", 
"72. ", 
"73. Late Acute Rejection", 
"74. Late Allograft Loss", 
"75. Long-Term Graft Function", 
"76. TOR Inhibitors", 
"77. Renal Function at 1 year Tac plus MMF vs SRL", 
"78. Tac plus MMF vs SRL Mendez et al Transplantation, 2005", 
"79. Tac plus MMF vs SRL Mendez et al Transplantation, 2005", 
"80. Approaches to CNI Toxicity", 
"81. boyle 5.jpg", 
"82. ", 
"83. Chronic Allograft Nephropathy CSA vs Azathioprine Bakker et al, KI, 2003", 
"84. ", 
"85. Renal function: serum creatinine", 
"86. RCT of CNI Withdrawal Using MMF Abramowicz et al Transplantation, 2002", 
"87. RCT of MMF Plus Half Dose CSA on Renal Function The Reference Study Frimat et al AJT, 2006",
"88. CAESAR-Study Design Vincenti et al ATC, 2005",
"89. CAESAR Primary End Point-Mean Measured GFR",
"90. Percentage of Patients with BPAR",
"91. TOR Inhibitors", 
"92. Wyeth Canada Release Aug 18, 2006", 
"93. MMF plus Tac vs SRL plus Thymo Larson et al AJT", 
"94. Iothalamate GFR in Tac vs SRL Treated Renal Transplant Recipients(plus Thymo) Larson et al AJT, 2006", 
"95. CAN in CSA vs Non CSA Groups Belatacept Study Vincenti et al NEJM, 2005", 
"96. Incidence of Chronic Allograft Damage in Patients Treated With and Without CNI Hamdy et al AJT, 2005", 
"97. Calculated Creatinine Clearance in ORION Pietruck et al WTC, 2006", 
"98. Graft Survival in SRL 310 CSA Withdrawal", 
"99. Calculated GFR in CNI Withdrawal Study 310 Oberbauer et al Transplant Int, 2005", 
"100. ", 
"101. Study Design", 
"102. Immunosuppressive Management", 
"103. Safety and Efficacy Stratum With Baseline GFR=20 to 40mL/min", 
"104. Similar Acute Rejection Rates*", 
"105. Preservation of GFR* Median Analysis(Modified ITT**)", 
"106. Study316: Renal Conversion(CONVERT) Factors Affecting Renal Function Campistol et al, WTC 2006", 
"107. ", 
"108. N=30 studies:2017 patients", 
"109. Randomized Trials-GFR", 
"110. Non-Randomized Studies-GFR", 
"111. Proportion Improved or Stabilized", 
"112. Predictors of Successful Conversion", 
"113. Predictors of Successful Conversion", 
"114. Predictors of Successful Conversion", 
"115. TOR Inhibitors and Malignancy",
"116. Skin Carcinoma(ITT)", 
"117. Malignancy Rates in Convert Study", 
"118. Study316: Renal Conversion(CONVERT) Malignancy Data (Pascoe, WTC 2006)", 
"119. Study Design Main Study 12 months", 
"120. Mean Calculated Creatinine Clearance", 
"121. Percentage of Patients with BPAR", 
"122. SYMPHONY: Comparison of 3 low-toxicity regimens with standard immunosuppression", 
"123. SYMPHONY Study Design", 
"124. Main Inclusion and Exclusion", 
"125. SYMPHONY Endpoints", 
"126. The Largest Prospective De Novo Kidney Transplant Study", 
"127. Demograhpics", 
"128. Demograhpics", 
"129. Renal Function Calculated GFR at month 12 (Cockeroft-Gault)", 
"130. Calculated GFR (Cockeroft-Gault)", 
"131. Biopsy Proven Acute Rejection(ITT, Excluding Borderline)", 
"132. ", 
"133. Graft and Patient Survival", 
"134. Safety", 
"135. Limitations", 